

Journal of Visualized Experiments

Using the protozoan *Paramecium caudatum* as a vehicle for food-borne infections in zebrafish larvae

--Manuscript Draft--

Article Type:	Methods Article - JoVE Produced Video
Manuscript Number:	JoVE58949R1
Full Title:	Using the protozoan <i>Paramecium caudatum</i> as a vehicle for food-borne infections in zebrafish larvae
Keywords:	Paramecia; <i>Paramecium caudatum</i> ; zebrafish; <i>Danio rerio</i> ; food-borne infection; enteric pathogens
Corresponding Author:	Anne-Marie Krachler University of Texas Health Science Center at Houston Houston, Texas UNITED STATES
Corresponding Author's Institution:	University of Texas Health Science Center at Houston
Corresponding Author E-Mail:	anne.marie.krachler@uth.tmc.edu
Order of Authors:	Erika Flores Laurel Thompson Natalie Sirisaengtaksin Anh Trinh Nguyen Abigail Ballard Anne-Marie Krachler
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Open Access (US\$4,200)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Houston, TX, USA

TITLE:

Using the Protozoan *Paramecium Caudatum* as a Vehicle for Food-Borne Infections in Zebrafish Larvae

AUTHORS AND AFFILIATIONS:

Erika Flores*, Laurel Thompson*, Natalie Sirisaengtaksin*, Anh Trinh Nguyen*, Abigail Ballard*, Anne Marie Krachler

University of Texas Health Science Center at Houston, McGovern Medical School, Department of Microbiology and Molecular Genetics, Houston, TX, USA

*These authors contributed equally.

Corresponding Author:

Anne Marie Krachler (Anne.Marie.Krachler@uth.tmc.edu)

Email Addresses of Co-authors:

Erika Flores	(Erika.Flores@uth.tmc.edu)
Laurel Thompson	(Laurel.Thompson@uth.tmc.edu)
Natalie Sirisaengtaksin	(Natalie.Sirisaengtaksin@uth.tmc.edu)
Anh Trinh Nguyen	(Anh.TrinhNguyen@uth.tmc.edu)
Abigail Ballard	(aballard15@austincollege.edu)

KEYWORDS:

Paramecia, *Paramecium caudatum*, zebrafish, *Danio rerio*, food-borne infection, enteric pathogens

SUMMARY:

Zebrafish (*Danio rerio*) are becoming a widely-used vertebrate animal model for microbial colonization and pathogenesis. This protocol describes the use of the protozoan *Paramecium caudatum* as a vehicle for food-borne infection in zebrafish larvae. *P. caudatum* readily internalizes bacteria and get taken up by larval zebrafish through natural preying behavior.

ABSTRACT:

Due to their transparency, genetic tractability, and ease of maintenance, zebrafish (*Danio rerio*) have become a widely-used vertebrate model for infectious diseases. Larval zebrafish naturally prey on the unicellular protozoan *Paramecium caudatum*. This protocol describes the use of *P. caudatum* as a vehicle for food-borne infection in larval zebrafish. *P. caudatum* internalize a wide range of bacteria and bacterial cells remain viable for several hours. Zebrafish then prey on *P. caudatum*, the bacterial load is released in the foregut upon digestion of the paramecium vehicle, and the bacteria colonize the intestinal tract. The protocol includes a detailed description of paramecia maintenance, loading with bacteria, determination of bacterial degradation and dose, as well as infection of zebrafish by feeding with paramecia. The advantage of using this method of food-borne infection is that it closely mimics the mode of infection observed in human disease,

leads to more robust colonization compared to immersion protocols, and allows the study of a wide range of pathogens. Food-borne infection in the zebrafish model can be used to investigate bacterial gene expression within the host, host-pathogen interactions, and hallmarks of pathogenicity including bacterial burden, localization, dissemination and morbidity.

INTRODUCTION:

Zebrafish share morphologically and functionally conserved features with mammals, including granulocytic lineages (e.g., neutrophils), monocyte/macrophage-like cells, Toll-like receptors, pro-inflammatory cytokines, and antimicrobial peptides¹. The intestinal tract in zebrafish is fully developed at 6 days post fertilization (dpf) and shows morphological and functional conservation with the mammalian gastrointestinal tract, such as conserved transcriptional regulation in intestinal epithelial cells². This makes zebrafish an excellent model for intestinal microbial colonization and pathogenesis. A wide range of enteric microbes has been studied in the zebrafish model, including enterohemorrhagic *Escherichia coli*³, *Vibrio cholerae*^{4,5}, *Salmonella enterica*⁶, the zebrafish microbiota^{7,8}, and the role of probiotics in intestinal immunity⁹. A distinct advantage of the zebrafish model is that it is colonized by many microbes without disrupting the endogenous microbiota, which allows the investigation of microbial behavior in the context of mixed microbial populations^{3,6}. Currently, most zebrafish models of gastrointestinal colonization and disease rely on the administration of microbes by bath immersion, where zebrafish are incubated in a bacterial suspension for a specific amount of time¹⁰. However, this makes it difficult to determine the exact dose of bacteria administered, and leads to limited colonization with some microbes, particularly with non-pathogenic bacteria. Alternatively, a bacterial suspension is administered to fish *via* oral gavage¹¹, but this is technically challenging and limited to older larvae and adult fish.

This protocol describes the use of the unicellular protozoan *Paramecium caudatum* as a vehicle for food-borne delivery of microbes to the gastrointestinal tract of zebrafish larvae. Paramecia are easy and cheap to maintain and are capable of feeding on a wide variety of microbes, including algae, fungi, and bacteria, which they internalize through a ciliated oral groove¹²⁻¹⁴. Once internalized, bacteria are held in vacuoles, which eventually acidify and contents are degraded over a time frame of several hours¹⁵. Larval zebrafish capture paramecia as natural prey soon after hatching, around 3 - 4 dpf depending on temperature¹⁶, and take them up with high efficiency. The process of prey capture takes on average 1.2 s from detection to capture¹⁷, and captured paramecia are quickly digested in the zebrafish foregut, such that internalized viable bacteria are released into the intestinal tract³. As a result, paramecia can be used as a quick and easy method to deliver a high and consistent dose of bacteria into the gastrointestinal tract of zebrafish. The delivered bacteria can either be transformed to express a fluorescent protein, such as mCherry as described here, or, in the case of genetically intractable bacteria, they can be pre-stained with a fluorescent dye to allow visualization within the gastrointestinal tract.

This protocol describes the food-borne delivery of enteropathogenic *E. coli* (enterohemorrhagic *E. coli* [EHEC] and adherent invasive *E. coli* [AIEC]), and *Salmonella enterica* ssp. Typhimurium. Both pathogenic *E. coli* and *S. typhimurium* are transmitted *via* the fecal-oral route^{18,19}, and can be acquired *via* contaminated food, such as meat, vegetables, and dairy. Using *P. caudatum* as a

vehicle, *E. coli* and *S. typhimurium* successfully colonize the zebrafish larvae within 30 - 60 min of co-incubation with the paramecium vehicle. The achieved bacterial burden is robust enough to visualize colonization and determine burden by plating tissue homogenates.

PROTOCOL:

Zebrafish care, breeding, and experiments described here are in accordance with the Guide for the Care and Use of Laboratory Animals, and have been approved by the Institutional Animal Welfare Committee of the University of Texas Health Science Center, protocol number AWC-16-0127.

1. Growth and Maintenance of Paramecia

1.1. Obtain live paramecia cultures from sources such as the Zebrafish International Resource Center (ZIRC).

1.2. From a live growing culture, add 1 mL of the paramecia culture, 1 mL of an *E. coli* MG1655 culture (optical density OD₆₀₀ 1.0 - 2.0) resuspended in 1x E3 (0.29 g/L NaCl, 13 mg/L KCl, 44 mg/L CaCl₂, 81 mg/L MgSO₄, 0.48 g/L HEPES, pH 7.0, sterile), and 8 mL of 1x E3 into a 10 mL tissue culture flask. Swirl lightly and then store at 22 °C.

1.3. To maintain a culture, every two weeks, passage 1 mL of a paramecia culture into a 10 mL tissue culture flask with 9 mL of fresh 1x E3 medium containing 10⁸ CFU/mL of *E. coli* MG1655 resuspended in 1x E3.

2. Determination of Bacterial Dose Administered to Zebrafish

2.1. Determine bacterial half-life within paramecium

NOTE: The half-life of bacteria within paramecia is determined by plating viable *E. coli* recovered from paramecium, as described below.

2.1.1. Following a 2 h incubation of bacteria (OD₆₀₀ of 1.0) with paramecia at 22 °C, combine the paramecia and bacterial co-culture into a 50 mL conical tube, wash the paramecia with 1x E3, and count the number of paramecia per milliliter (as described below in steps 3.2.7 and 3.2.8).

2.1.2. After counting the number of paramecia, remove 50 µL of the paramecia and bacterial co-culture every hour (for 6 h post-exposure) and add each sample into a fresh 1.5 mL tube.

2.1.3. Place 950 µL of 1% nonionic surfactant (see **Table of Materials**) in phosphate buffered saline (PBS) solution into each of the 1.5 mL tubes and vortex for 1 min to lyse the paramecia. Perform 1:10 dilutions of each sample using sterile PBS as a diluent (*i.e.*, 100 µL in 900 µL).

2.1.4. Plate 100 µL of each dilution onto selective plates (LB tet medium: 1 g/L tryptone, 0.5 g/L yeast extract, 1 g/L NaCl, 30 µg/mL tetracycline) and incubate at 37 °C for 16 h. The next day,

count and record the number of bacterial colonies on the plate (colony forming units, CFUs) by counting only the isolated and distinct individual colonies. Identify a plate with a dilution that gives 30 - 300 CFU.

2.1.5. Determine the dilution factor used. For example, if 1 µL of the bacterial culture is mixed with 99 mL of sterile PBS, this is a 1:100 (0.01) dilution. This number will be the number of CFU in the dilution. Perform the calculation below, for every time point, to determine the CFU in the original sample:

$$\frac{\text{CFU from dilution}}{\text{Dilution factor} \times \text{volume plated}} = \text{CFU in original sample}$$

2.1.6. Calculate and graph the number of viable *E. coli*/paramecium corresponding to the hours post exposure using the paramecia concentration calculated in step 3.3.1 and determine the half-life within the paramecia (**Figure 1**).

2.1.7. Using the CFU number calculated for each time point, calculate and graph the number of viable *E. coli* per paramecium on the y-axis *versus* the hours post incubation on the x-axis, using the paramecia concentration calculated in step 3.3.1. Determine the half-life within the paramecia.

2.2. Determine bacterial dosing from bacterial half-life and preying rate.

NOTE: To determine the bacterial dosage, the half-life of the bacteria inside the paramecia and the preying rate of zebrafish on paramecia (see step 3.4) have to be taken into account.

2.2.1. Use the following formula to determine bacterial decay within paramecia:

$$(1) \quad Nt = N_0 e^{-k\tau}$$

Where N_0 is the initial quantity of bacteria per paramecia after the 2 h incubation, Nt is the remaining quantity after time t , τ is the time after which the number of viable bacteria has halved, and k is the decay constant.

2.2.2. From the degradation experiment, determine the decay constant k using the bacterial half-life (*i.e.*, the time after which the amount of viable bacteria/paramecium has halved).

$$(2) \quad \ln \left(\frac{Nt}{N_0} \right) = -k * \tau$$

For the determination of half-life, the term $\frac{Nt}{N_0} = \frac{1}{2}$ and

$$(3) \quad \ln \left(\frac{1}{2} \right) = -k * \tau \text{ or}$$

$$(4) \quad k = -\frac{\ln \frac{1}{2}}{\tau}$$

NOTE: Based on **Figure 1**, the half-life of *E. coli* in paramecia is approximately 2.3 h. Thus, using formula (4), the decay rate, k , for *E. coli* is:

$$(5) \quad k = -\frac{\ln \frac{1}{2}}{\tau} = -\frac{\ln \frac{1}{2}}{2.3} = 0.30 \cdot h^{-1}$$

2.2.3. Determine the decay rate (k) from the half-life experiment to find the dose of viable bacteria (Nt) taken up by the zebrafish larvae after preying time (t), where (P) is the preying rate or the number of paramecia eaten by one fish per hour:

$$(6) \quad \ln \frac{Nt}{N_0 \cdot P} = -k \cdot t \text{ or}$$

$$(7) \quad \text{Dosage } Nt = \frac{P \cdot N_0}{e^{k \cdot t}}$$

NOTE: Per **Figure 1**, the initial quantity of bacteria per paramecia (N_0) after a 2 h incubation (t) is 790 CFU. Per **Movie 1** and **Figure 2**, the preying rate (P) is 1539.

2.2.4. Using these values to substitute into equation (7), calculate the bacterial dosage consumed by a zebrafish following a 2 h incubation as:

$$(8) \quad \text{Dosage } Nt = \frac{P \cdot N_0}{e^{k \cdot t}} = \frac{1539 \cdot 790}{e^{0.30 \cdot 2}} = 6.7 \cdot 10^5 \text{ CFU}$$

3. Food-borne Infection of Zebrafish

3.1. Incubate bacteria with paramecia.

3.1.1. Prepare a co-culture of paramecia and *E. coli* MG1655 the night prior to infection. Combine 8 mL of E3 media, 1 mL of an ongoing paramecia culture, and 1 mL of an *E. coli* MG1655 culture ($OD_{600} = 1.0$) resuspended in 1x E3 in T25 tissue culture flasks. Incubate the flasks at room temperature (RT) overnight. For each treatment condition, prepare two flasks of paramecia.

3.1.2. Inoculate bacterial growth media (LB: 1 g/L tryptone, 0.5 g/L yeast extract, 1 g/L NaCl) with infectious strain of bacteria, by picking an individual bacterial colony from a plate using a sterile inoculation loop. Incubate the liquid culture at 37 °C and leave shaking at 110 rotations per minute (rpm) overnight.

NOTE: Personal protective equipment (a laboratory coat and gloves) should be worn and biosafety level 2 facilities should be used when handling infectious agents.

214 3.1.3. On the next day, measure the OD₆₀₀ of the overnight culture. Calculate the volume of
215 culture required to achieve an OD₆₀₀ of 1 when resuspended in 11 mL of media.

216
217 3.1.4. Harvest the volume of bacteria from step 3.1.2 *via* centrifugation at 6000 x g for 5 min,
218 one volume for each flask of paramecia. Discard the supernatant and resuspend the bacterial
219 pellet in 1 mL of E3 media.

220
221 3.1.5. Optionally, pre-stain the bacteria with a fluorescent dye.

222
223 3.1.5.1. Add 1 µL of FM 4-64FX bacterial stain (5 mg/mL stock solution). Cover tube with foil to
224 protect from photobleaching and incubate rotating end-over-end at RT for 15 min.

225
226 3.1.5.2. Remove excess dye by washing with 1x E3: Pellet bacteria *via* centrifugation at 6000 x g
227 for 1.5 min, then resuspend pellet in 1 mL of E3 media. Repeat wash step two times.

228
229 3.1.5.3. Harvest stained bacteria *via* centrifugation at 6000 x g for 5 min. Discard the supernatant
230 and resuspend the bacterial pellet in 1 mL of E3 media.

231
232 3.1.6. Add 1 mL of the bacterial suspensions to each of the two flasks of fresh paramecia.
233 Incubate at RT for 2 h.

234
235 NOTE: If working with stained bacteria, incubate in the dark at RT for 2 h.

236
237 3.2. Wash bacteria/paramecia co-culture.

238
239 3.2.1. Combine the contents of both flasks of paramecia/bacteria co-culture into a 50 mL conical
240 tube. Centrifuge samples at 300 x g at 15 °C for 10 min. Make sure that the centrifuge is pre-
241 cooled prior to this step.

242
243 3.2.2. Remove approximately 10 mL of the E3 supernatant using a serological pipette and add
244 approximately 10 mL of fresh 1x E3 to the conical tube.

245
246 NOTE: During all wash steps, it is essential to be very quick when removing the supernatant, as
247 the paramecia will begin to swim out of the pellet. Spin and remove supernatant from one tube
248 at a time to ensure quick enough handling at this step, and avoid loss of paramecia in the
249 supernatant.

250
251 3.2.3. Spin samples *via* centrifugation at 300 x g at 15 °C for 5 min. Remove approximately 10
252 mL of the E3 supernatant using a serological pipette, and add approximately 10 mL of fresh 1x E3
253 to the conical tube. Repeat this step twice.

254
255 3.2.4. Centrifuge samples at 300 x g at 15 °C for 5 min. Remove approximately 10 mL of the E3
256 supernatant, taking care not to disrupt the pellet.

257

3.2.5. Resuspend pellet into the remaining 10 mL of E3 media and transfer 500 µL of the suspension into a new 1.5 mL microcentrifuge tube. Pellet the 500 µL of paramecia by centrifuging at 300 x g for 5 min to count the number of paramecia.

3.2.6. Remove 400 µL of the E3 supernatant from the 500 µL sample. Add 20 µL of 36.5% formaldehyde solution to the remaining 100 µL of paramecia and gently resuspend, and incubate for 5 min at 22 °C.

NOTE: This step kills the paramecia to allow for counting.

3.2.7. Measure actual total volume using the pipette and record. Dilute the paramecia suspension 1:1 v/v with 0.4% trypan blue solution.

3.2.8. Use a cell counter or hemocytometer to count the number of dead paramecia/mL.

NOTE: Because of the prior fixation step, most paramecia will be dead at this point, but this number reflect the number of live paramecia for the co-incubation experiment. The authors have not found significant paramecia death due to bacterial co-incubation, so this can be disregarded as a factor here.

3.3. Co-incubate Paramecia and zebrafish larvae.

3.3.1. Calculate the concentration of paramecia:

$$\frac{500 \mu\text{L}}{\text{measured volume (from step 3.2.7)}} = \text{dilution factor}$$

$$\frac{\text{measured paramecia concentration (step 3.2.8)}}{\text{dilution factor}} = \text{original paramecia concentration}$$

NOTE: This calculation gives the concentration of paramecia in the 50 mL conical tube from step 3.2.5.

3.3.2. Calculate the volume of washed paramecia required for a concentration of 2×10^5 paramecia/mL in a final volume of 3 mL of E3.

NOTE: The concentration of paramecia can be adjusted based on the desired bacterial dosage, which is subject to optimization.

3.3.3. Anesthetize zebrafish by adding tricaine in 100 mM Tris pH 8.0 to a final concentration of 100 mg/L. Transfer 10 zebrafish into each well of a 6-well plate into a total volume of 3 mL of fresh E3 containing the appropriate concentration of paramecia (calculated in step 3.3.2). Ensure to transfer larvae in a minimal amount of liquid, to ensure they recover from anesthesia in the recipient well.

3.3.4. Incubate at 30 °C for 2 h in a diurnal incubator under day-light conditions, to ensure optimal lightning conditions for preying.

3.3.5. Wash zebrafish at least 5 times by transferring fish into a new well containing 3 mL of fresh E3 containing 100 mg/L tricaine each time.

NOTE: Do not attempt to omit the tricaine during the washing step. Transferring mobile larvae without anesthesia increases the risk of damage and distress to the animal.

3.3.6. Optionally, prepare zebrafish for imaging by embedding zebrafish in 3 mL of 1% low-melt agarose in a black-walled 6-well plate: Low-melt agarose is made up in 1xE3 and heated in a microwave. Once molten, add tricaine to a final concentration of 160 mg/mL. Position fish under a stereomicroscope, using a clipped gel loading tip, making sure that the head is on the left and the tail is on the right (**Figure 3**). Wait for 5 minutes for the agarose to set, then overlay the embedded fish with 1xE3 containing 160 mg/mL tricaine for imaging.

3.4. Determine the preying rate.

NOTE: No separate experiment needs to be set up to determine the preying rate. Rather, this can be done during step 3.3.4., as described below.

3.4.1. During step 3.3.4, view preying zebrafish on a stereomicroscope and capture video footage of the prey capture.

3.4.2. Score the video footage. Prey capture is characterized by striking of zebrafish toward the prey. Count each strike as one prey capture event, although this is only an approximation (see **Discussion**).

3.4.3. Calculate the average number of prey capture events per hour from multiple video clips, each representing a different zebrafish larva (**Figure 2**).

REPRESENTATIVE RESULTS:

Paramecium caudatum readily internalizes a wide range of bacteria into storage vacuoles. The intracellular bacterial density depends on the densities of bacteria and paramecia in the co-culture, as well as the bacterial species used. Over time, the vacuoles acidify and bacterial degradation ensues. The rate of degradation has to be individually determined for all strains used. For pathogenic *E. coli*, the initial bacterial density is 790 bacteria/paramecium, and bacteria are degraded with a half-life of approximately 2.3 h (**Figure 1**).

[Place Figure 1 here.]

Further, the zebrafish preying rate, that is, the rate at which zebrafish internalize bacteria-loaded paramecia upon co-incubation, was studied. Larval zebrafish start to hunt and capture live prey

from 5 dpf²⁰, although it was found that, when raised at 30 °C, larval development is accelerated and animals display preying behavior from 4 dpf. Preying is accompanied by a characteristic striking behavior²⁰ (**Figure 2A**), and the determination of the preying rate is based on the assumption that each strike leads to internalization of one paramecium, although this can only be regarded an approximation (see **Discussion**). Based on the herein described observations of preying zebrafish larvae, the rate of paramecia uptake is approximately 1539 per hour (**Figure 2B**).

[Place Figure 2 here.]

Following internalization of paramecia, the zebrafish efficiently degrades the prey in the foregut, releasing infectious bacteria into the digestive system. As described herein, paramecia degradation proceeds quickly, and free bacteria can be detected in the intestinal tract within 30 minutes of preying. Free bacteria then move from the foregut to the mid- and posterior intestine, where they are detected approximately 1 - 2 h after the beginning of preying (**Figure 3**). Bacterial persistence in the intestine depends on species and dose but ranges from several hours to several days in the case of *E. coli* and *S. enterica*. *S. enterica* localizes primarily in the intestinal mucosae, with some epithelial invasion (**Figure 3D**), leading to infiltration of neutrophils into the epithelium (**Figure 3C**).

[Place Figure 3 here.]

FIGURE AND TABLE LEGENDS:

Figure 1: Determination of bacterial half-life in paramecia. (A) Following 2 hours of co-incubation with infectious *E. coli*, *P. caudatum* was washed and transferred to medium without bacteria. At the indicated time points, numbers of viable *E. coli* cells were determined by dilution plating on selective agar. Results are means \pm standard error of the mean (SEM; n = 3). (B) Typical image of paramecium carrying internalized bacteria, with bright field (Bi), fluorescent bacteria (Bii), and merged channels (Biii). Scale bar, 20 μ m.

Figure 2: Determination of zebrafish preying rate. (A) Still images from a preying video, showing a zebrafish larvae (5 dpf) preying on paramecia carrying fluorescent bacteria. Time in [seconds]. Arrow indicates the main axis of movement during striking. (B) Quantification of preying rate (paramecia intake per hour), based on n = 10 videos taken over the full 2-hour exposure time.

Figure 3: Colonization of zebrafish with bacteria. Zebrafish at 5 dpf were left uninfected (A) or colonized with mCherry expressing (B) *E. coli* or (C) *S. enterica*. Infection experiments may be performed in wild type (A and B) fish or transgenic lines (e.g., the line Tg(MPO::EGFP)¹¹⁴ expressing green fluorescent neutrophils shown in (C). The rectal opening is marked by an arrow. (D) Higher magnification of intestinal section from whole-mount embedded larvae infected with *Salmonella enterica* infection. (Di) Blue – Hoechst marking nuclei, (Dii) Purple – phalloidin marking F-actin, (Diii) Red – *Salmonella*, (Div) merge. Scale bar, 5 μ m.

Movie 1: Video footage of the prey capture.

DISCUSSION:

The basic protocol described here has been optimized for pathogenic *E. coli*, and has been successfully adapted for other bacterial species, including *Salmonella enterica* and *Vibrio cholerae*. For some species that do not colonize the zebrafish gut following bath immersion, including some *Salmonella enterica* strains and some anaerobes, food-borne infection as described here can be used to successfully establish colonization. Compared to microgavage, which is also used to establish high bacterial burdens in the larval intestinal tract, food-borne infection is technically less challenging and requires less specialized equipment. However, critical parameters should be optimized for the bacterial species and strains to be used. Such factors include bacterial and paramecium density for the bacteria-paramecium co-culture step: If bacterial numbers within paramecia are low, this could be improved by increasing the bacterial density in the co-culture step. Some bacterial species may cause damage to the paramecium host, and this should be assessed by microscopy.

Another important factor in this protocol is prey capture by zebrafish. The preying rate as described here is based on the assumption that every prey capture strike results in the ingestion of one paramecium. High densities of paramecia per fish are used in the protocol to ensure high preying rates. However, prey capture is dependent on the density of paramecia in the system, and in very dilute paramecium cultures, preying rates may be as low as 13 - 15 paramecia per hour^{21,22}. A limitation is that prey capture rates are also strongly dependent on lighting conditions and in the dark, capture rates are 80% lower than in light conditions²¹ and this should be taken into account when setting up experiments. If exposure times to prey have to be expanded to optimize colonization, consideration has to be given to secondary exposure to bacteria through feces. Under the conditions described above – 2 hours of prey exposure – this exposure is negligible, since gut passage time of bacteria is more than 1 h and the concentration of bacteria in the vehicle is much higher than in feces. However, if prey exposure time is significantly increased, this may become a significant factor.

Appropriate controls should be included in this protocol, including colonization of zebrafish following feeding with paramecia containing non-pathogenic *E. coli* MG1655. If multiple bacterial strains are compared for their ability to colonize the zebrafish host, it is important to test whether their half-life within paramecia is comparable. Bacterial mutations, including those compromising cell wall integrity or acid sensing, may compromise bacterial stability within paramecia. In such cases, zebrafish feeding has to be adjusted to account for the differences in dosage.

The protocol described here can be used to investigate bacterial colonization and its consequences, including by imaging bacterial colonization of zebrafish as described above, as well as by determining CFU per zebrafish from tissue homogenate³, or investigating infection-associated morbidity and mortality. Ideally, for bacterial visualization, bacterial strains expressing fluorescent proteins such as mCherry or red fluorescent protein (RFP) should be used. This will allow the visualization of growing bacterial populations. If the bacterial strain is not genetically tractable or the use of fluorescent protein expression is precluded for other reasons, bacteria

may be stained with a fluorescent dye, such as FM 4-64FX, prior to co-culture with paramecia. When using the protocol described here, co-culture with paramecia does not decrease the brightness of the dye and stained bacteria are clearly visible in the zebrafish intestine. However, the dye will be diluted over time should significant bacterial proliferation occur within the zebrafish host. In either case, red-fluorescent bacteria are preferable over green-fluorescent bacteria, since tissue autofluorescence can be higher in the green than in the red channel.

It has been found that this protocol can be adapted for aerobic and microaerophilic bacterial species. It may be possible to adapt it for the feeding of spores and fungal species, although this remains to be tested experimentally.

ACKNOWLEDGMENTS:

We would like to thank members of the Krachler group for critical reading and comments on the manuscript. This work was funded by a UT Systems STAR award, the BBSRC, and the NIH (R01AI132354).

DISCLOSURES:

The authors have nothing to disclose.

REFERENCES:

- 1 Broz, P., Ohlson, M. B., Monack, D. M. Innate immune response to *Salmonella* Typhimurium, a model enteric pathogen. *Gut Microbes*. **3** (2), 62-70 (2012).
- 2 Lickwar, C. R. *et al.* Genomic dissection of conserved transcriptional regulation in intestinal epithelial cells. *PLoS Biology*. **15** (8), e2002054 (2017).
- 3 Stones, D. H. *et al.* Zebrafish (*Danio rerio*) as a Vertebrate Model Host To Study Colonization, Pathogenesis, and Transmission of Foodborne *Escherichia coli* O157. *mSphere*. **2** (5), (2017).
- 4 Mitchell, K. C., Breen, P., Britton, S., Neely, M. N., Withey, J. H. Quantifying *Vibrio cholerae* enterotoxigenicity in a zebrafish infection model. *Applied and Environmental Microbiology*. 10.1128/AEM.00783-17, (2017).
- 5 Logan, S. L. *et al.* The *Vibrio cholerae* type VI secretion system can modulate host intestinal mechanics to displace gut bacterial symbionts. *Proceedings of the National Academy of Sciences of the United States of America*. **115** (16), E3779-E3787 (2018).
- 6 Howlader, D. R. *et al.* Zebrafish as a novel model for non-typhoidal *Salmonella* pathogenesis, transmission and vaccine efficacy. *Vaccine*. **34** (42), 5099-5106, (2016).
- 7 Troll, J. V. *et al.* Microbiota promote secretory cell determination in the intestinal epithelium by modulating host Notch signaling. *Development*. **145** (4), (2018).
- 8 Wiles, T. J. *et al.* Host Gut Motility Promotes Competitive Exclusion within a Model Intestinal Microbiota. *PLoS Biology*. **14** (7), e1002517 (2016).
- 9 Rendueles, O. *et al.* A new zebrafish model of oro-intestinal pathogen colonization reveals a key role for adhesion in protection by probiotic bacteria. *PLoS Pathogens*. **8** (7), e1002815 (2012).
- 10 Varas, M. *et al.* *Salmonella* Typhimurium induces cloacitis-like symptoms in zebrafish larvae. *Microbial Pathogenesis*. **107**, 317-320 (2017).

476 11 Runft, D. L. *et al.* Zebrafish as a natural host model for *Vibrio cholerae* colonization and
477 transmission. *Applied and Environmental Microbiology*. **80** (5), 1710-1717 (2014).

478 12 Meier, R., Wiessner, W. Infection of algae-free *Paramecium bursaria* with symbiotic
479 *Chlorella* sp. Isolated from green paramecia: I. Effect of the incubation period. *European Journal*
480 *of Protistology*. **24** (1), 69-74 (1988).

481 13 Miura, T., Moriya, H., Iwai, S. Assessing phagotrophy in the mixotrophic ciliate
482 *Paramecium bursaria* using GFP-expressing yeast cells. *FEMS Microbiology Letters*. **364** (12),
483 (2017).

484 14 Watanabe, K. *et al.* Ciliate *Paramecium* is a natural reservoir of *Legionella pneumophila*.
485 *Scientific Reports*. **6**, 24322, (2016).

486 15 Bragg, A. N., Hulpieu, H. A Method of Demonstrating Acidity of Food Vacuoles in
487 *Paramecium*. *Science*. **61** (1580), 392 (1925).

488 16 Borla, M. A., Palecek, B., Budick, S., O'Malley, D. M. Prey capture by larval zebrafish:
489 evidence for fine axial motor control. *Brain, Behavior and Evolution*. **60** (4), 207-229 (2002).

490 17 Patterson, B. W., Abraham, A. O., MacIver, M. A., McLean, D. L. Visually guided gradation
491 of prey capture movements in larval zebrafish. *Journal of Experimental Biology*. **216** (Pt 16), 3071-
492 3083 (2013).


493 18 Megraud, F. Transmission of *Helicobacter pylori*: faecal-oral *versus* oral-oral route.
494 *Alimentary Pharmacology & Therapeutics*. **9 Suppl 2**, 85-91 (1995).


495 19 Spears, K. J., Roe, A. J., Gally, D. L. A comparison of enteropathogenic and
496 enterohaemorrhagic *Escherichia coli* pathogenesis. *FEMS Microbiology Letters*. **255** (2), 187-202
497 (2006).


498 20 Bianco, I. H., Kampff, A. R., Engert, F. Prey capture behavior evoked by simple visual
499 stimuli in larval zebrafish. *Frontiers in Systems Neuroscience*. **5**, 101 (2011).


500 21 Gahtan, E., Tanger, P., Baier, H. Visual prey capture in larval zebrafish is controlled by
501 identified reticulospinal neurons downstream of the tectum. *Journal of Neuroscience*. **25** (40),
502 9294-9303 (2005).

503 22 Westphal, R. E., O'Malley, D. M. Fusion of locomotor maneuvers, and improving sensory
504 capabilities, give rise to the flexible homing strikes of juvenile zebrafish. *Frontiers in Neural*
505 *Circuits*. **7**, 108 (2013).









Click here to access/download
Video or Animated Figure
PreyCapture.mp4

Name of Material/ Equipment	Company	Catalog Number
<i>Paramecium caudatum</i> , live	Carolina	131554
0.4% Trypan Blue Solution	Sigma	T8154-20ML
Dimethyl sulfoxide (DMSO)	Sigma	276855-100ML
<i>Escherichia coli</i> , MG1655	ATCC	ATCC 700926
FM 4-64FX stain	Thermo Fisher	F34653
Formaldehyde	Sigma	F8775-4X25ML
LB Broth	Sigma	L3397-1KG
Phosphate buffered saline tablets	Thermo Fisher	18912014
Tetracycline	Sigma	87128-25G
Tricaine (Ethyl 3-aminobenzoate methanesulfonate)	Sigma	E10521-10G
Triton X-100	Sigma	X100-100ML
Trypan Blue Solution, 0.4%	Sigma	93595-50ML
UltraPure Low Melting Point Agarose	Thermo Fisher	16520050
hemocytometer or cell counter	any	
stereomicroscope	any	
table-top centrifuge		
microwave		
rotator wheel		
heated shaking incubator		
aquatics facilities		
breeding tanks		

Comments/Description

no not store growing cultures below room temperature

liquid, sterile-filtered, suitable for cell culture; prepared in 0.81% sodium chloride and 0.06% potassium phosphate, dibasic

store in a solvent safety cabinet

can be replaced by any other non-pathogenic *E. coli* strain

aliquot and store frozen

toxic, irritant



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Using the protozoan *Paramecium caudatum* as a vehicle for food-borne infections in zebrafish larvae

Author(s):

Flores, Thompson, Sirisaengtaksin, Nguyen, Ballard, Krachler.

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:

☐ Standard Access

☒ Open Access

Item 2: Please select one of the following items:

☒ The Author is **NOT** a United States government employee.

☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.

☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: "**Agreement**" means this Article and Video License Agreement; "**Article**" means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; "**Author**" means the author who is a signatory to this Agreement; "**Collective Work**" means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; "**CRC License**" means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; "**Derivative Work**" means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; "**Institution**" means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; "**JOVE**" means MyJOVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; "**Materials**" means the Article and / or the Video; "**Parties**" means the Author and JOVE; "**Video**" means any video(s) made by the Author, alone or in conjunction with any other parties, or by JOVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JOVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JOVE agreeing to publish the Article, the Author hereby grants to JOVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JOVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. Indemnification. The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to

the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. Fees. To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. Transfer, Governing Law. This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

CORRESPONDING AUTHOR

Name:

Anne-Marie Krachler

Department:

Microbiology & Molecular Genetics


Institution:

University of Texas Health Science Center Houston

Title:

Associate Professor

Signature:



Date:

8/15/2018

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140



McGovern
Medical School

Microbiology and Molecular Genetics

Anne-Marie Krachler, Ph.D.
Associate Professor

September 17, 2018

Re: Manuscript JoVE58949

Dear Editor,

Please find enclosed our revised manuscript entitled '**Using the protozoan *Paramecium caudatum* as a vehicle for food-borne infections in zebrafish larvae**'. We would like to thank you and the reviewers for your positive responses and really appreciate your suggestions on how to improve our work. We have updated the manuscript to reflect our response to your comments. Please find attached below a detailed breakdown of our response to the editorial and the reviewers' comments and resulting changes to the manuscript. We hope you will now find our work suitable for publication.

Sincerely,



Anne-Marie Krachler, Ph.D.
Associate Professor of Microbiology and Molecular Genetics

Response to Editorial comments:

1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues. – *We proofread the manuscript.*
2. JoVE cannot publish manuscripts containing commercial language. This includes trademark symbols (™), registered symbols (®), and company names before an instrument or reagent. Please remove all commercial language from your manuscript and use generic terms instead. – All commercial products should be sufficiently referenced in the Table of Materials and Reagents. You may use the generic term followed by “(see table of materials)” to draw the readers’ attention to specific commercial names. Examples of commercial sounding language in your manuscript are: falcon, Triton, FM 4-64FX, etc. – *We replaced Falcon tube with conical tube. Triton and FM 4-64 are specific reagents, which cannot be replaced by other, generic reagents.*
3. Please revise the protocol text to avoid the use of any personal pronouns (e.g., “we”, “you”, “our” etc.). – *We have edited the protocol to avoid these phrases.*
4. Please revise the protocol to contain only action items that direct the reader to do something (e.g., “Do this,” “Ensure that,” etc.). The actions should be described in the imperative tense in complete sentences wherever possible. Avoid usage of phrases such as “could be,” “should be,” and “would be” throughout the Protocol. – *We have amended this, except in the Discussion section where we feel these phrases are appropriate.*
Any text that cannot be written in the imperative tense may be added as a “Note.” Please include all safety procedures and use of hoods, etc. However, notes should be used sparingly and actions should be described in the imperative tense wherever possible.
5. Please add more details to your protocol steps. There should be enough detail in each step to supplement the actions seen in the video so that viewers can easily replicate the protocol. Please ensure you answer the “how” question, i.e., how is the step performed? Alternatively, add references to published material specifying how to perform the protocol action. See examples below:
 - 1.2: What is E3? Please provide its composition. What is taken from a live growing culture? It is unclear. – *We have added the composition of E3 upon its first mention in section 1.2.*
 - 1.3: How to measure density and what is the peak density? – *We do not actually measure the culture density, and have removed the corresponding phrasing.*
 - 2.1.1: What is the incubation temperature? What is used to wash the paramecia? How to count the number? Steps 4.1 and 4.2 do not exist.- *We have added the incubation temperature and amended the reference to the correct steps.*
 - 2.1.5: What are the selective plates and how to count CFUs? – *We have added a description of the media composition and a more detailed description of the CFU counting.*
 - 2.1.6: Please provide an equation if possible. – *We have now provided an equation.*
 - 3.1.3: Please describe how to inoculate bacterial growth media with infectious strain of bacteria. Please provide composition of bacterial growth media. – *We have added the medium composition and procedure.*
 - 3.1.6: Step 4.1.5 does not exist. Should it be 3.1.5? Yes, corrected.
 - 3.1.8.3: What is used to wash? Please specify the wash step repeated here. – *We added that the wash is performed with 1xE3.*
 - 3.2.3: What is used to remove the supernatant? – *Added that a serological pipette is used.*
 - 3.2.9: What is the incubation temperature? – *Added the incubation temperature.*
 - 3.3.1: Steps 4.2.10 and 4.2.6 mentioned in this step do not exist. Please revise. – *Amended.*
 - 3.3.3: Step 4.3.2 does not exist. Please revise.- *Amended to 3.3.2.*
6. 2.2 and sub-steps: Can these steps be moved after step 3.3.4. As currently organized, the readers/viewers have to refer back and forth in order to complete the protocol.- *We have moved this section to the end of the protocol.*

7. 2.3.1 and 2.3.2: Please break up into sub-steps.- *We broke it up into sub-steps.*
8. Please combine some of the shorter Protocol steps so that individual steps contain 2-3 actions and maximum of 4 sentences per step. – *We have combined steps wherever we thought possible.*
9. After you have made all the recommended changes to your protocol (listed above), please highlight 2.75 pages or less of the Protocol (including headings and spacing) that identifies the essential steps of the protocol for the video, i.e., the steps that should be visualized to tell the most cohesive story of the Protocol.
10. Please highlight complete sentences (not parts of sentences). Please ensure that the highlighted part of the step includes at least one action that is written in imperative tense. Please do not highlight any steps describing anesthetization and euthanasia. Please note that calculation steps are not appropriate for filming.
11. Please include all relevant details that are required to perform the step in the highlighting. For example: If step 2.5 is highlighted for filming and the details of how to perform the step are given in steps 2.5.1 and 2.5.2, then the sub-steps where the details are provided must be highlighted.
12. Figure 2: Please state the unit of time in panel A in the figure legend. – *Included in figure legend.*
13. Discussion: Please discuss any limitations of the technique and the significance with respect to existing methods. – *We have included some more discussion of limitations and comparison with existing techniques.*
14. References: Please do not abbreviate journal titles.

Reviewers' comments:

Reviewer #1:

Manuscript Summary:

good, detailed procedure to produce a useful experimental tool. Only minor concerns that can be addressed in text and possibly with addition of already existing data

Minor Concerns:

Line 249 reference to 4.1.5 should be 3.1.5 – *Thank you, this has been corrected.*

274 insight into gravitational tolerance of paramecium would be nice. Does harder for shorter kill the paramecium or can they tolerate a shorter spin at higher g? – *We use the minimal force required to pellet them efficiently, and see no benefit in increasing the spin force.*

277 recommend pipette or decanting to rapidly remove supernatant without disturbing motile pellet? – *We added to add a serological pipette for this step.*

296 I assume a standard 4% PFA? PFA is missing from materials section – *We have specified the formaldehyde concentration and added the reagent to the materials list.*

320 why is it necessary for the embryos to be knocked out prior to transfer? – *Anesthetizing the embryos facilitates fast and efficient transfer and minimizes distress and risk of causing damage to the animals.*

324 please add necessity of lighting to achieve high/reproducible prey rates. Is lab bench lighting sufficient or is more direct light required? – *We have added the note: 'Incubation should be carried out in a diurnal incubator under day-light conditions, to ensure optimal lightning conditions for preying.'*

333 add homogenisation and plating steps and indicative results – *The halflife experiment does not as such contain a homogenization step. The plating step is described in step 2.1.5, and representative results in Fig. 1.*

Reviewer #2:

Manuscript Summary:

In this manuscript, Flores and colleagues describe using paramecia as a delivery system for pathogenic bacteria into the intestines of larval zebrafish. Zebrafish is increasingly being used as a model for investigating gnotobiology and bacterial pathogenesis, so this approach is timely and should be very useful to the research community. However, as described below, there are issues that need to be resolved before this manuscript can be published and used as the basis for a video.

Major Concerns:

- 1) At the beginning of the protocol, the experiments are described as being in accordance with the Animal Scientific Procedures Act 1986 which is from the UK. Since the work is covered by a University of Texas Health Science Center Institutional Animal Welfare Committee protocol number, the authors should change this to the Guide for the Care and Use of Laboratory Animals, or something else specific to the US. – *The section has been amended accordingly.*
- 2) A list of abbreviations and solutions would be useful. – *we have added the composition of E3, and formaldehyde, which are the only relevant solutions.*
- 3) In step 2.1.2, are the samples from different time points added to the same 1.5mL tube? Or is each sample added to a different tube? It doesn't make sense to me why all of the samples would be added together. But reading the protocol it isn't clear that they aren't. Assuming there are different tubes for each time point, then 2.1.3 should say tubes plural, rather than tube singular, which reinforces the idea that all the samples go into a single tube. – *They all go into separate tubes, and we have edited the section to improve clarity.*
- 4) In step 2.2.2 and lines 352-359 the authors define the number of prey capture events as the number of strikes. They acknowledge, in the discussion, that the number of strikes and the number of prey captures aren't necessarily the same. I think it would be useful to include that information here, or at least include a reference to the discussion. – *We have added references to the Discussion in step 2.2.2. and in the representative results section, as suggested.*
- 5) It's not at all clear what is shown in Figure 2. The authors should have pictures that include both a larva and the fluorescent bacteria. And why is the entire larva, including the eyes, fluorescing in red? – *As explained in the legend, Figure 2 shows a larva preying on paramecia that carry internalized bacteria (small round objects in the frames). Single bacteria would be too small to visualize at this magnification. To visualize the larva movements, we have to use both the red fluorescent channel, as well as a minimal amount of bright field backlighting. The latter leads to the red appearance of the larvae, which is the only way to track both larva and paramecia for these videos.*
- 6) How do the authors know that the bacteria in Figure 3 are alive? *Dead bacteria, when visualized under the microscope, rapidly lose membrane integrity and thus, fail to contain fluorescence.*
- 7) Most of the fluorescence in Figure 3 is in intestinal epithelial cells, not in bacteria. It would be useful to include a blow up that shows both the autofluorescent intestinal epithelial cells and the fluorescent bacteria. – *We have added an uninfected control fish to Figure 3, which highlights that there is little to no autofluorescence in the red channel coming from the epithelial cells. The reason the epithelium appears red is because the bacteria are tightly associated with the*

mucosae and, to some extent, invade the epithelium. To highlight this, we have added a series of higher magnification images (Fig. 3D), which show bacterial localization in respect to the intestinal epithelium.

8) The equations in 3.3.1 have several errors. First, there is no step 4.2.10. Second, I don't see how parametia concentration/dilution factor can equal the dilution factor. Third, there is no step 4.2.6. – *We have amended the formula, to reflect both the correct step numbers as well as the correct algebra.*

9) What is the dosing experiment of step 3.3 that is referred to in 3.3.2? – *We have edited the text to read ' The concentration of parametia can be adjusted based on the desired bacterial dosage, which is subject to optimization.'*

10) 3.3.3 would be easier to follow if broken up into two steps - first anesthetize the larvae and place them in a well with fresh E3 - and second add the parametia. Alternatively, first prepare the well with fresh E3 and parametia - and second add anesthetized larvae. It also needs to be made clear whether the larvae are still anesthetized when they are in the well with the parametia. I wouldn't think so, as they wouldn't be able to hunt, but this isn't clear from the manuscript. If the larvae are not anesthetized when they are in the well, why are they anesthetized first? Is this just for handling purposes? And when is the anesthesia removed? This should all be clarified. – *We have edited this step for clarity. The larvae are anaesthetized for ease of handling and to reduce the risk of damage and distress. The target well does not contain tricaine, and care has to be taken to transfer the larvae with a minimal amount of liquid to ensure they recover from anesthesia once they reach the recipient well.*

11) In 3.3.5 are the fish transferred from well to well for the five washes? Or is the tricaine E3 sucked out of the well? Does this matter? Does it matter whether the larvae are anesthetized? – *Yes, and each well has E3 plus tricaine. This minimizes chances to do damage and cause distress to the animal, which we have now added to the text.*

12) More information should be given about the embedding step in 3.3.6. – *We have added more detail regarding the embedding step.*

13) Line 222-223 refer to video 1 which was not made available to review. – *We have added the video to the uploaded files.*

Minor Concerns:

1) Unclear why some of the protocol has yellow highlighting.- *This is a requirement of the journal for video purposes.*

2) What are the units of preying rate? [s^{-1}]

3) In 3.1.3, or elsewhere, it would be prudent to say something about appropriate PPE to wear while working with infectious bacteria. – *We have added a note to that effect to the inoculation step.*

4) 3.1.6 refers to 4.1.5. But there is no 4.1.5. – *Amended to 3.1.5.*

5) There is an extra with in 3.1.8.2. – *Thank you, has been removed.*

6) More detail on the washing would be useful in 3.1.8.3. – *We have specified number, volume,*

and media used for washes, as well as centrifugation speed to be used.

7) 3.1.9 has an extra the. – *Thanks, this has been removed.*

8) Why are two flasks used in 3.1.9 and then the contents combined in 3.2.1? – *We use 2 T-25 flasks containing 10 ml each, since this guarantees optimal aeration of the cultures.*

9) In 3.2.6 is the remaining E3 what is left in the tube after removing as much as possible in the previous step? *We edited this and the prior steps to enhance clarity.*

10) What is the final concentration of tricaine used for anesthesia? *For transfer steps, we use 0.1 mg/L of tricaine, and for embedding and long-term procedures 160 mg/L tricaine, as noted in the manuscript.*

Reviewer #3:

Manuscript Summary:

This protocol describes the use of the protozoan *Paramecium caudatum* as a vehicle for food-borne infection in zebrafish larvae.

Major Concerns:

1. Is there a stable phase of bacteria dose in the paramecia after co-incubation? – *There might be a short (few minute-long) plateau prior to acidification which might be considered a stable phase. However, since this timeframe is very short in comparison to co-incubation and subsequent gut transit time, we found it more practical to consider bacterial half-life using the formulas presented in the manuscript to work out the dose of viable bacteria at any given point during incubation.*

2. Is it considered that the bacteria in the feces could be prey again? – *Over the timeframe of prey exposure (2hrs – gut passage time is more than 1 hr), and considering the relative concentration of bacteria in paramecium vs in feces, this constitutes a negligible contribution. We have added this consideration to the discussion.*

3. Line 304. Counting the dead paramecia. In co-incubation of *Paramecia* and zebrafish larvae protocol, whether the dead paramecia should be removed? – *The paramecia will be dead because of the formaldehyde fixation at this point, but this number will reflect the concentration of live paramecia for the co-incubation experiment. We have determined that co-incubation with bacteria does not result in significant death of paramecia, but rather in proliferation, so this can be disregarded and no removal is necessary. We have added a note to explain this.*

Minor Concerns:

Explain the E3 medium.- *We have added a description of contents upon first mention.*